Lindi Barla

MedScaler provides market entry consulting to micro and small businesses looking to scale MedTech innovations in the Netherlands and Europe. Responsible for expanding MedScaler’s European network and products.

Supported analytics heavy clients in the Benelux. Internally additionally focused on learning and development (organized +/-40 learning activities) and recruitment. Since 2017 part of the talent development program. Also part of global 'Consultants as Partners' initiative to improve client partnerships, thought leadership and internal process efficiencies, leading to estimated company savings of $1.500.000 in 1 years’ time. Global reach of >2000 FactSet employees managing 30 ambassadors.

Got acquainted with the finance industry in my role as a consultant for a leading provider of financial data and analytic applications in the industry, serving i.a. banks, insurers, pension funds.

Worked for the Healthcare Innovation Transfer as part of the Consulate General of the Netherlands. Performed research on business models of incubators and accelerators and their value to startups in healthcare.

SHC is a platform for young entrepreneurs in healthcare. Wrote the SHC business plan and together with 5 other board members we organized 4 events to accelerate ideas into new businesses with support in cash and kind and recruited >20 corporate partners and >30 start-ups in year 1.

Provided research for new focus and direction for the hospital boards of VUmc, AMC and UMC on technological innovations. Additionally, performed a clinical study on thermographic imaging at the VUmc department Physics & Medical Technology.

DCTF promotes clinical research in the Netherlands and is involved with implementation of EU regulations in the field via stakeholders such as hospitals, universities pharmaceutical companies.

For Bsc thesis built a dataset (incl. 3yr FDA drug safety notifications) for research discussing perceived safety of biopharmaceuticals vs small molecule medicines. Research conclusions were contrary to expectations, which led to exploration of opportunities for scientific publication of the findings.

Compared the effectiveness of different treatments for breast cancer and reported an advice on the implementation of Ibrance® (drug received accelerated approval from the FDA in Feb 2015).

Specialization: Science, Business and Innovation on Life and Health

Education track: life and health

Public speaking, sociology, social anthropology, political philosophy and archaeology